TY - JOUR
T1 - The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia
AU - Hägerstrand, Daniel
AU - Oder, Blaž
AU - Cortese, Diego
AU - Qu, Ying
AU - Binzer-Panchal, Amrei
AU - Österholm, Cecilia
AU - Del Peso Santos, Teresa
AU - Rabbani, Leily
AU - Asl, Hassan Foroughi
AU - Skaftason, Aron
AU - Ljungström, Viktor
AU - Lundholm, August
AU - Koutroumani, Maria
AU - Haider, Zahra
AU - Jylhä, Cecilia
AU - Mollstedt, John
AU - Mansouri, Larry
AU - Plevova, Karla
AU - Agathangelidis, Andreas
AU - Scarfò, Lydia
AU - Armand, Marine
AU - Muggen, Alice F.
AU - Kay, Neil E.
AU - Shanafelt, Tait
AU - Rossi, Davide
AU - Orre, Lukas M.
AU - Pospisilova, Sarka
AU - Barylyuk, Konstantin
AU - Davi, Frederic
AU - Vesterlund, Mattias
AU - Langerak, Anton W.
AU - Lehtiö, Janne
AU - Ghia, Paolo
AU - Stamatopoulos, Kostas
AU - Sutton, Lesley Ann
AU - Rosenquist, Richard
N1 - Publisher Copyright: © The Author(s) 2024.
PY - 2024/11
Y1 - 2024/11
N2 - SF3B1 mutations are recurrent in chronic lymphocytic leukemia (CLL), particularly enriched in clinically aggressive stereotyped subset #2. To investigate their impact, we conducted RNA-sequencing of 18 SF3B1MUT and 17 SF3B1WT subset #2 cases and identified 80 significant alternative splicing events (ASEs). Notable ASEs concerned exon inclusion in the non-canonical BAF (ncBAF) chromatin remodeling complex subunit, BRD9, and splice variants in eight additional ncBAF complex interactors. Long-read RNA-sequencing confirmed the presence of splice variants, and extended analysis of 139 CLL cases corroborated their association with SF3B1 mutations. Overexpression of SF3B1K700E induced exon inclusion in BRD9, resulting in a novel splice isoform with an alternative C-terminus. Protein interactome analysis of the BRD9 splice isoform revealed augmented ncBAF complex interaction, while exhibiting decreased binding of auxiliary proteins, including SPEN, BRCA2, and CHD9. Additionally, integrative multi-omics analysis identified a ncBAF complex-bound gene quartet on chromosome 1 with higher expression levels and more accessible chromatin in SF3B1MUT CLL. Finally, Cancer Dependency Map analysis and BRD9 inhibition displayed BRD9 dependency and sensitivity in cell lines and primary CLL cells. In conclusion, spliceosome dysregulation caused by SF3B1 mutations leads to multiple ASEs and an altered ncBAF complex interactome, highlighting a novel pathobiological mechanism in SF3B1MUT CLL. (Figure presented.)
AB - SF3B1 mutations are recurrent in chronic lymphocytic leukemia (CLL), particularly enriched in clinically aggressive stereotyped subset #2. To investigate their impact, we conducted RNA-sequencing of 18 SF3B1MUT and 17 SF3B1WT subset #2 cases and identified 80 significant alternative splicing events (ASEs). Notable ASEs concerned exon inclusion in the non-canonical BAF (ncBAF) chromatin remodeling complex subunit, BRD9, and splice variants in eight additional ncBAF complex interactors. Long-read RNA-sequencing confirmed the presence of splice variants, and extended analysis of 139 CLL cases corroborated their association with SF3B1 mutations. Overexpression of SF3B1K700E induced exon inclusion in BRD9, resulting in a novel splice isoform with an alternative C-terminus. Protein interactome analysis of the BRD9 splice isoform revealed augmented ncBAF complex interaction, while exhibiting decreased binding of auxiliary proteins, including SPEN, BRCA2, and CHD9. Additionally, integrative multi-omics analysis identified a ncBAF complex-bound gene quartet on chromosome 1 with higher expression levels and more accessible chromatin in SF3B1MUT CLL. Finally, Cancer Dependency Map analysis and BRD9 inhibition displayed BRD9 dependency and sensitivity in cell lines and primary CLL cells. In conclusion, spliceosome dysregulation caused by SF3B1 mutations leads to multiple ASEs and an altered ncBAF complex interactome, highlighting a novel pathobiological mechanism in SF3B1MUT CLL. (Figure presented.)
UR - https://www.scopus.com/pages/publications/85203490484
U2 - 10.1038/s41375-024-02379-4
DO - 10.1038/s41375-024-02379-4
M3 - Article
C2 - 39261602
AN - SCOPUS:85203490484
SN - 0887-6924
VL - 38
SP - 2429
EP - 2442
JO - Leukemia
JF - Leukemia
IS - 11
ER -